2010, ISBN: 9781617374364

[ED: Softcover], [PU: Humana / Humana Press / Springer, Berlin], Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor marker… Más…

[ED: Softcover], [PU: Humana / Humana Press / Springer, Berlin], Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. It is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy. 2010. xii, 342 S. XII, 342 p. 22 illus. 229 mm Versandfertig in 6-10 Tagen, DE, [SC: 0.00], Neuware, gewerbliches Angebot, Offene Rechnung (Vorkasse vorbehalten)<

2001, ISBN: 9781617374364

[ED: Taschenbuch], [PU: SPRINGER NATURE], Neuware - Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine… Más…

[ED: Taschenbuch], [PU: SPRINGER NATURE], Neuware - Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. It is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy., DE, [SC: 0.00], Neuware, gewerbliches Angebot, 229x152x19 mm, 342, [GW: 476g], Banküberweisung, Offene Rechnung, Kreditkarte, PayPal, Offene Rechnung (Vorkasse vorbehalten), Internationaler Versand<

2001, ISBN: 9781617374364

[ED: Taschenbuch], [PU: SPRINGER NATURE], Neuware - Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine… Más…

[ED: Taschenbuch], [PU: SPRINGER NATURE], Neuware - Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. It is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy., DE, [SC: 2.70], Neuware, gewerbliches Angebot, 229x152x19 mm, 342, [GW: 476g], Banküberweisung, Offene Rechnung, Kreditkarte, PayPal, Offene Rechnung (Vorkasse vorbehalten), Internationaler Versand<

2010, ISBN: 1617374369

[EAN: 9781617374364], Neubuch, [SC: 10.99], [PU: Springer Nature Singapore], CONSUMER HEALTH; HEALTH & FITNESS / DISEASES CANCER; MEDICAL ONCOLOGY, Druck auf Anfrage Neuware - Printed aft… Más…

[EAN: 9781617374364], Neubuch, [SC: 10.99], [PU: Springer Nature Singapore], CONSUMER HEALTH; HEALTH & FITNESS / DISEASES CANCER; MEDICAL ONCOLOGY, Druck auf Anfrage Neuware - Printed after ordering - Expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers and examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines for the validation studies of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. It is now well recognized that individualized cancer treatment planning, based on tumor characteristics specific to an individual's cancer, makes it easier to select those most likely to benefit from toxic cancer therapies and to avoid treating those least likely to benefit. In Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect, expert laboratory and clinical researchers from around the world review how to design and evaluate studies of tumor markers, as well as examine their use in breast cancer patients. The authors cover both the major advances in sophisticated molecular methods and the state-of-the-art in conventional prognostic and predictive indicators. Among the topics discussed are the relevance of rigorous study design and guidelines to the validation of new biomarkers, gene expression profiling by tissue microarrays, adjuvant systemic therapy, and the use of estrogen, progesterone, and epidermal growth factor receptors as both prognostic and predictive indicators. Highlights include the evaluation of HER2 and EGFR family members, of p53, and of UPA/PAI-1; the detection of rare cells in blood and marrow; and the detection and analysis of soluble, circulating markers. Authoritative and cutting-edge, Biomarkers in Breast Cancer: Molecular Diagnostics for Predicting and Monitoring Therapeutic Effect offers laboratory investigators developing new tumor markers, clinical investigators testing them, and clinicians using them an up-to-date understanding of both the prognostic/predictive indicators and the novel molecular-targeted therapies suitable for individualizing breast cancer therapy., Books<

2010, ISBN: 9781617374364

Paperback, New., 342 p. Cancer Drug Discovery and Development . 22 Illustrations, black and white; XII, 342 p. 22 illus. Intended for professional and scholarly audience., Totowa, NJ, [PU… Más…

Paperback, New., 342 p. Cancer Drug Discovery and Development . 22 Illustrations, black and white; XII, 342 p. 22 illus. Intended for professional and scholarly audience., Totowa, NJ, [PU: Humana Press Inc.]<